As genetic testing becomes more accessible, how are companies incorporating these technologies into their strategy?
RWE has become increasingly important in supporting supplemental or conditional drug approvals. Where is the space headed?
What are the implications of the DHHS' new plan to overhaul prescription drug rebates for federal beneficiaries?
Key guiding principles for effective forecasting, common pitfalls, and how to use a forecast to develop better strategy
Launching a new therapy is a complex endeavor. We will review the various activities key to a successful drug launch.
How can flexibility in clinical development can be incorporated at various points along an asset’s life cycle
Principal Sam Ulin will give a presentation on The Landscape of Innovation 2019: Drivers of Value for Innovators on June 3, 2018.
Navigating new challenges of market access and reimbursement for new pharmaceuticals in today's market
Recent changes in the orphan drug market access landscape and implications for pharmaceutical developers
Distinct ways that medtech companies can incorporate digital health technologies into their portfolios
Investing early in PAGs’ success is a sound strategic move that may increase a company’s chances of success by forming a collaboration that enhances patient access
Building a well thought-out plan to establish evidence of safety and of clinical utility to establish trust in a new platform
Technical and transactional assessments required to identify the right type of partnership for a biotech’s asset or platform and overall business needs